Hackensack, NJ - April 17, 2023 –
Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic (PPMO) integration, announced the launch of its therapeutic discovery and development platform into a wholly owned subsidiary named Corellia AI (Corellia). Corellia launches out of Champions Oncology with a team of world class scientists advancing a robust pipeline of therapeutic programs and a unique discovery and development platform. The company will continue to leverage Champions' superior PDX Molecular Atlas and its living bank of PDX models as central tools in its proprietary target and therapeutic discovery platform.
